1VTRS Stock Chart & Stats
€15.46
€0.25(1.70%)
At close: 4:00 PM EDT
€15.46
€0.25(1.70%)
Day’s Range― - ―
52-Week Range€5.00 - €23.00
Previous CloseN/A
Volume0.00
Average Volume (3M)230.00
Market Cap
€15.93B
Enterprise Value€30.69K
Total Cash (Recent Filing)€1.51B
Total Debt (Recent Filing)€13.63B
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Nov 09, 2026EPS Estimate
0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding1,148,590,800
10 Day Avg. Volume195
30 Day Avg. Volume230
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.72Price Target Upside1.70% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)2.15
Revenue Forecast (FY)€12.80B
Bulls Say, Bears Say
Bulls Say
Robust Cash GenerationSustained operating cash flow (~$2.7B TTM) and strong free cash flow (~$2.2B, ~30% growth) provide durable internal funding for debt reduction, R&D, launches and buybacks. Reliable cash generation de-risks operations while management rebuilds consistent profitability over coming quarters.
Improving Leverage And LiquidityDebt reduction from prior years and a debt-to-equity near 0.94 reflect a clearer capital structure and better refinancing optionality. Extended maturities and recent note issuance support liquidity, enabling strategic investment and capital returns without materially constraining operational flexibility.
Pipeline, Approvals & Complex Product MomentumRegulatory wins and a deep development pipeline, including biosimilars, complex generics and Gwyn Lo approval, expand sustainable revenue channels beyond commodity generics. New product approvals and late‑stage programs support higher‑margin growth and reduce reliance on low‑margin volumes over multiple quarters.
Bears Say
Persistent Net Losses And Margin PressureDespite cash strength, recurring negative net income and a slide in gross margins signal structural pricing, mix or cost challenges. Until operating profitability stabilizes, equity returns and reinvestment plans remain constrained and earnings volatility may persist across several quarters.
Manufacturing Supply Risks (Nashik)A facility fire and FDA inspection at Nashik created material H2 supply headwinds (~$100–$150M revenue impact). Recurrent plant issues heighten the risk of product shortages and customer switching, pressuring volumes and margins until remediation and capacity resilience are demonstrably restored.
Policy And Competitive Pressure In China And Developed MarketsExposure to China procurement shifts and intense competition in branded/generic products creates structural revenue tailwinds and margin headwinds. Provincial policy execution uncertainty and product‑level competition can mute growth and pricing power for multiple quarters across key geographies.
Viatris News
1VTRS FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest stock price was €5.00 and its highest was €23.00 in the past 12 months.
What is Viatris’s market cap?
Viatris’s market cap is €15.93B.
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is Nov 09, 2026 which is in 86 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Aug 06, 2026. The company reported €0.597 earnings per share for the quarter, beating the consensus estimate of €0.52 by €0.077.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Undervalued.
Does Viatris pay dividends?
Viatris does not currently pay dividends.
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is 0.56.
How many shares outstanding does Viatris have?
Viatris has 1,148,590,800 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of €0.597 in its last earnings report, beating expectations of €0.52. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of Viatris?
Currently, no hedge funds are holding shares in IT:1VTRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€15.72 (1.70% Upside)
€15.72 (1.70% Upside)
Blogger Sentiment
Neutral
IT:1VTRS Sentiment 55%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.66%
12-Months-Change
Fundamentals
Return on Equity
2.95%
Trailing 12-Months
Asset Growth
-8.77%
Trailing 12-Months
Company Description
Viatris
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
1VTRS Company Deck
1VTRS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive operational and strategic momentum: the company beat expectations in Q2 on revenue, EBITDA and EPS, raised full-year guidance across key metrics, showed margin improvement, strong cash generation, aggressive capital returns, meaningful pipeline and regulatory progress (Gwyn Lo approval, Nefecon topline, Phase III programs on track). Offsetting this, notable near-term challenges include Nashik manufacturing disruptions (with a $100–$150 million H2 revenue headwind), emerging markets supply constraints, competitive pressure in some developed-market products, and China procurement policy uncertainty that may moderate future growth. Overall, management framed the challenges as mostly short-term and fully considered in the updated guidance while emphasizing long-term growth opportunities and financial flexibility.View all IT:1VTRS earnings summaries1VTRS Net sales Breakdown
64.45% Brands
35.55% Generics
1VTRS Stock 12 Month Forecast
Average Price Target
€15.72
▲(1.70% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―